Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Awakn Life Sciences
(OTCQB:AWKNF)
Intraday
$0.1304
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$0.1304
0
[0.00%]
Last update: 9:31AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Awakn Life Sciences Stock (OTC:AWKNF)
Awakn Life Sciences Stock (OTC: AWKNF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 17, 2024
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Lara Goldstein
-
6 days ago
Thursday, February 15, 2024
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Lara Goldstein
-
Feb 15, 2024, 10:55AM
Friday, January 26, 2024
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Lara Goldstein
-
Jan 26, 2024, 12:33PM
Wednesday, December 27, 2023
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
Lara Goldstein
-
Dec 27, 2023, 10:09AM
Thursday, December 21, 2023
Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
The Dales Report
-
Dec 21, 2023, 1:13PM
Friday, November 24, 2023
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Lara Goldstein
-
Nov 24, 2023, 9:44AM
Wednesday, November 15, 2023
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
Lara Goldstein
-
Nov 15, 2023, 4:20PM
Sunday, October 15, 2023
U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
Lara Goldstein
-
Oct 15, 2023, 8:06PM
Monday, September 11, 2023
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Lara Goldstein
-
Sep 11, 2023, 9:34AM
Wednesday, September 06, 2023
Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
The Dales Report
-
Sep 6, 2023, 5:27PM
Monday, August 14, 2023
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Lara Goldstein
-
Aug 14, 2023, 9:46AM
Thursday, August 03, 2023
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
Lara Goldstein
-
Aug 3, 2023, 8:52AM
Tuesday, August 01, 2023
Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics
Lara Goldstein
-
Aug 1, 2023, 1:09PM
Wednesday, July 26, 2023
Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
The Dales Report
-
Jul 26, 2023, 2:27PM
Tuesday, July 11, 2023
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
Lara Goldstein
-
Jul 11, 2023, 11:25AM
Wednesday, July 05, 2023
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
Lara Goldstein
-
Jul 5, 2023, 1:53PM
Tuesday, June 20, 2023
Psyched: $75M In Federal Funds, Gov. Polis Opens MAPS Event, CNN's Show, Dock Ellis' LSD Pitch & More
Lara Goldstein
-
Jun 20, 2023, 5:01PM
Thursday, June 15, 2023
Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement
Lara Goldstein
-
Jun 15, 2023, 8:17PM
Monday, June 12, 2023
Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
Lara Goldstein
-
Jun 12, 2023, 3:18PM
Monday, May 01, 2023
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Lara Goldstein
-
May 1, 2023, 7:06PM
Friday, April 28, 2023
Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
Lara Goldstein
-
Apr 28, 2023, 12:57PM
Monday, April 24, 2023
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Lara Goldstein
-
Apr 24, 2023, 3:57PM
Wednesday, April 19, 2023
Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
Lara Goldstein
-
Apr 19, 2023, 11:25AM
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
Lara Goldstein
-
Apr 19, 2023, 10:04AM
Monday, April 17, 2023
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Lara Goldstein
-
Apr 17, 2023, 4:14PM
Friday, April 14, 2023
Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
Lara Goldstein
-
Apr 14, 2023, 12:24PM
Sunday, March 19, 2023
EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility
Lara Goldstein
-
Mar 19, 2023, 9:01AM
Monday, March 13, 2023
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
Lara Goldstein
-
Mar 13, 2023, 9:30AM
Tuesday, March 07, 2023
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Lara Goldstein
-
Mar 7, 2023, 10:29AM
Thursday, March 02, 2023
MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production
Lara Goldstein
-
Mar 2, 2023, 2:50PM
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California
Lara Goldstein
-
Mar 2, 2023, 8:56AM
Monday, February 27, 2023
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Lara Goldstein
-
Feb 27, 2023, 7:28PM
Wednesday, February 22, 2023
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Lara Goldstein
-
Feb 22, 2023, 1:28PM
Tuesday, February 21, 2023
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Lara Goldstein
-
Feb 21, 2023, 5:19PM
Tuesday, February 14, 2023
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Lara Goldstein
-
Feb 14, 2023, 2:25PM
Monday, February 13, 2023
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Lara Goldstein
-
Feb 13, 2023, 4:01PM
Thursday, February 09, 2023
A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
Lara Goldstein
-
Feb 9, 2023, 4:56PM
Tuesday, February 07, 2023
Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status
Lara Goldstein
-
Feb 7, 2023, 11:10AM
Tuesday, January 24, 2023
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Lara Goldstein
-
Jan 24, 2023, 6:01PM
Wednesday, January 04, 2023
These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
Lara Goldstein
-
Jan 4, 2023, 11:48AM
Monday, December 19, 2022
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Lara Goldstein
-
Dec 19, 2022, 8:23PM
Friday, December 16, 2022
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Lara Goldstein
-
Dec 16, 2022, 4:54PM
Tuesday, December 13, 2022
UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites
Lara Goldstein
-
Dec 13, 2022, 3:35PM
Tuesday, December 06, 2022
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Lara Goldstein
-
Dec 6, 2022, 2:20PM
Saturday, December 03, 2022
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic
Lara Goldstein
-
Dec 3, 2022, 2:00PM
Tuesday, November 29, 2022
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
Lara Goldstein
-
Nov 29, 2022, 12:15PM
Wednesday, November 23, 2022
A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest
Lara Goldstein
-
Nov 23, 2022, 1:27PM
Tuesday, November 15, 2022
Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup
Lara Goldstein
-
Nov 15, 2022, 11:46AM
Wednesday, November 09, 2022
EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC
Lara Goldstein
-
Nov 9, 2022, 7:00AM
Show more
